

---

Cochrane Database of Systematic Reviews - - Cochrane Review

# Systematic review of the safety and efficacy of palivizumab among infants and young children with cystic fibrosis.

**Code:** PM28423192    **Year:** 2017    **Date:** 2019 - updated: 22 NOV 2021

**Author:** Kua KP

## Study design (if review, criteria of inclusion for studies)

Randomized and quasi-randomized trials of different medical interventions compared to each other or to no intervention or to placebo.

## Participants

Patients with CF and rhinosinusitis

## Interventions

medical interventions (e. g. different concentrations of nasal saline irrigations, topical or oral corticosteroids, antibiotics including nebulized antibiotics, dornase alfa and modulators of the cystic fibrosis transmembrane conductance regulator (CFTR) such as lumacaftor, ivacaftor or tezacaftor) compared to each other or to no intervention or to placebo

## Outcome measures

improvement of rhinosinusitis, preventing pulmonary exacerbations, improving quality of life

## Main results

We identified no trials that met the pre-defined inclusion criteria. The most recent searches identified 44 new references, none of which were eligible for inclusion in the current version of this review; 12 studies are listed as excluded and one as ongoing.

## Authors' conclusions

We identified no eligible trials assessing the medical interventions in people with cystic fibrosis and chronic rhinosinusitis. High-quality trials are needed which should assess the efficacy of different treatment options detailed above for managing chronic rhinosinusitis, preventing pulmonary exacerbations and improving quality of life in people with cystic fibrosis.

<http://dx.doi.org/10.1002/phar.1936>

## See also

Pharmacotherapy. 2017 Apr 19. doi: 10.1002/phar.1936.

## Keywords

Adolescent; Adult; Bacterial Infections; Child; Deoxyribonuclease; Infection; Inhalation OR nebulised; nebuliser; non pharmacological intervention - devices OR physiotherapy; pharmacological\_intervention; Recombinant Proteins; Respiratory Tract Infections; Sinusitis; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents; Respiratory Tract Diseases; Dornase alpha; Pulmozyme; Hypertonic Solutions; isotonic Solutions;